Genzyme has announced new magnetic resonance imaging (MRI) data from the Lemtrada clinical development program.
In relapsing remitting multiple sclerosis (RRMS) patients treated with Lemtrada in the Phase III pivotal studies, MRI effects observed in the two-year trials were maintained through two additional years in the extension study (years three and four). After the initial two courses of treatment in the pivotal studies, which were given at month zero and at month 12, approximately 70 percent of Lemtrada patients did not receive additional Lemtrada treatment during the following three years, through month 48............. Read More - http://www.ms-uk.org/lemtrada
Study finds brain atrophy reduces in Lemtrada patients
Study finds brain atrophy reduces in Lemtrada patients
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1439 Views
-
Last post by NHE
-
- 0 Replies
- 11574 Views
-
Last post by accordingnature495
-
- 0 Replies
- 1753 Views
-
Last post by NHE
-
- 4 Replies
- 1517 Views
-
Last post by NHE
-
- 0 Replies
- 1219 Views
-
Last post by NHE
-
- 0 Replies
- 1549 Views
-
Last post by NHE
-
- 0 Replies
- 2017 Views
-
Last post by frodo
-
- 0 Replies
- 705 Views
-
Last post by frodo
-
- 3 Replies
- 4878 Views
-
Last post by NHE